Roth Capital Predicts Higher Earnings for Fortress Biotech

Key Points

• Roth Capital has raised its Q3 2025 earnings per share estimate for Fortress Biotech to ($0.21), up from a previous estimate of ($0.24), with full-year earnings expectations for 2025 set at ($1.30) EPS.
• Despite these revised estimates, Fortress Biotech's stock has recently traded down by 6.4% and opened at $2.05, with a market capitalization of approximately $60.99 million.
• Fortress Biotech's recent quarterly results showed earnings of ($0.46) per share, missing consensus estimates by $0.15, although the company reported revenue of $16.41 million, exceeding analyst projections.

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Investment analysts at Roth Capital raised their Q3 2025 earnings per share estimates for shares of Fortress Biotech in a research note issued to investors on Monday, August 18th. Roth Capital analyst J. Wittes now anticipates that the biopharmaceutical company will post earnings of ($0.21) per share for the quarter, up from their previous estimate of ($0.24). The consensus estimate for Fortress Biotech's current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($0.40) EPS.

Fortress Biotech Trading Down 6.4%

Shares of FBIO stock opened at $2.05 on Thursday. Fortress Biotech has a fifty-two week low of $1.33 and a fifty-two week high of $2.36. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.55 and a current ratio of 1.92. The stock's fifty day moving average is $1.91 and its two-hundred day moving average is $1.77. The firm has a market capitalization of $60.99 million, a P/E ratio of -1.95 and a beta of 1.76.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.15). Fortress Biotech had a negative return on equity of 301.81% and a negative net margin of 24.84%.The firm had revenue of $16.41 million during the quarter, compared to analyst estimates of $14.53 million.

Institutional Trading of Fortress Biotech

Several large investors have recently bought and sold shares of FBIO. Jane Street Group LLC acquired a new stake in Fortress Biotech in the 4th quarter valued at about $69,000. Envestnet Asset Management Inc. grew its position in shares of Fortress Biotech by 30.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 239,594 shares of the biopharmaceutical company's stock valued at $485,000 after purchasing an additional 55,648 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Fortress Biotech in the fourth quarter valued at approximately $109,000. PFG Investments LLC lifted its position in Fortress Biotech by 28.4% during the first quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 10,000 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Fortress Biotech by 8.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,004,365 shares of the biopharmaceutical company's stock worth $1,567,000 after buying an additional 80,058 shares during the last quarter. Hedge funds and other institutional investors own 96.51% of the company's stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.